Author:
Tong Sebastian T.,Ma Kris Pui Kwan,Pleho Ajla,Keiser Brennan,Hsu Chialing,Ehde Dawn M.,Curran Mary C.,Tsui Judith I.,Raue Patrick J.,Stephens Kari A.
Abstract
Abstract
Background
Patients with chronic pain on opioids frequently experience loneliness, which is associated with poorer health outcomes and higher risk for opioid misuse and opioid use disorder. Given that almost half of opioids are prescribed in primary care, a critical need exists for the development and testing of interventions to reduce loneliness in primary care patients at risk for opioid misuse. Cognitive behavioral therapy and social prescribing have been shown to be efficacious in reducing loneliness and improving outcomes in other populations but have not been tested in patients at risk for substance use disorder. The overall objective of our study is to reduce opioid misuse and opioid use disorder by addressing loneliness in patients on long-term opioid therapy in real-world primary care settings.
Methods
We will conduct a 3-arm pragmatic, randomized controlled trial to compare the effectiveness of two group-based, telehealth-delivered interventions with treatment as usual: (1) cognitive behavioral therapy to address maladaptive thought patterns and behaviors around social connection and (2) a social prescribing intervention to connect participants with social opportunities and develop supportive social networks. Our primary outcome is loneliness as measured by the UCLA Loneliness Scale and our dependent secondary outcome is opioid misuse as measured by the Common Opioid Misuse Measure. We will recruit 102 patients on long-term opioid therapy who screen positive for loneliness from 2 health care systems in Washington State. Implementation outcomes will be assessed using the RE-AIM framework.
Discussion
Our study is innovative because we are targeting loneliness, an under-addressed but critical social risk factor that may prevent opioid misuse and use disorder in the setting where most patients are receiving their opioid prescriptions for chronic pain. If successful, the project will have a positive impact in reducing loneliness, reducing opioid misuse, improving function and preventing substance use disorder.
Trial Registration
NCT06285032, issue date: February 28, 2024, original.
Funder
National Institute on Drug Abuse
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Ingram I, Kelly PJ, Deane FP, Baker AL, Goh MC, Raftery DK, Dingle GA. Loneliness among people with substance use problems: a narrative systematic review. Drug Alcohol Rev. 2020;39(5):447–83.
2. National Institute on Drug Abuse. Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery 2022 [cited 2022 13 Jul]. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-010.html
3. Pai N, Vella S-L. COVID-19 and loneliness: a rapid systematic review. Australian New Z J Psychiatry. 2021;55(12):1144–56.
4. Killgore WD, Cloonan SA, Taylor EC, Dailey NS. Loneliness: a signature mental health concern in the era of COVID-19. Psychiatry Res. 2020;290:113117.
5. Loades ME, Chatburn E, Higson-Sweeney N, Reynolds S, Shafran R, Brigden A, Linney C, McManus MN, Borwick C, Crawley E. Rapid systematic review: the impact of social isolation and loneliness on the mental health of children and adolescents in the context of COVID-19. J Am Acad Child Adolesc Psychiatry. 2020;59(11):1218–39. e3.